Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

Tumor samples were collected from two patients who developed resistance to ACT targeting NY-ESO-1, one with synovial sarcoma the other with undifferentiated pleomorphic sarcoma (UPS). For the patient with synovial sarcoma, biopsies (n=3; primary, metastasis, and recurrence) were subjected to bulk tumor DNA and RNA sequencing, as well as high-dimensional spatial profiling of RNA and protein targets. Bulk tumor whole exome and RNA sequencing corresponding to all three tumor specimens and whole exome sequencing from patient-matched normal blood are made available through this accession. For the patient with UPS, biopsies (n=2; primary and recurrence) were subjected to bulk tumor RNA sequencing, which are available through this accession.